Roche's (RHHBY.OB)  breast cancer drug T-DM1 "significantly" extended the lives of patients in a...

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche's (RHHBY.OB)  breast cancer drug T-DM1 "significantly" extended the lives of patients in a Phase III trial, a precondition for European regulators approving the treatment. Roche is developing T-DM1 with technology it has licensed from ImmunoGen (IMGN), which is rocketing 17.05% premarket. An analyst estimates that peak sales of T-DM1 could reach 1.6B Swiss francs ($1.67B). (PR)